3Rd B H,Lebrun F,Rugo H S,et al.Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3,randomized,controlled,BOLERO-2 trial.[J].Cancer,2013,119(10):1908.
8Jordan V C,Lewis J S,Osipo C,et al.The apoptotic action of estrogen following exhaustive antihormonal therapy:a new clinical treatment strategy[J].Breast,2005,14(6):624.
9Zhang Y,Simondsen K,Kolesar J M.Exemestane for primary prevention of breast cancer in postmenopausal women[J].Am J Health Syst Pharm,2012,69(16):1384.
6Nabholtz JM,Buzdar A,Pollak M,et al.Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:resuhs of a North American multicenter randomized trial[J].J Clin Oncol,2000,18(22):3758-3767.
7Bonneterre J,Thuflimann B,Robertson JF,et al.Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the tamoxifen or arimidex randomized group efficacy and tolerability study[J].J Clin Oncol,2000,18(22):3748-3757.
8Mouridsen H,Gershanovich M,Sun Y,et al.Phase Ⅲ study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopansal women:analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group[J].J Clin Oncol,2003,21(11):2101-2109.
9Dombernowsky P,Smith I,Falkson G.Letrozole,a new oral aromatase inhibitor for advanced breast cancer:,double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate[J].J Clin Oncol,1998,16(2):453-461.
10Kaufmann M,Bajetta E,Dirix LY,et al.Exemestane is superior to megestrol acetate following tarnoxifen failure in postmenopausal women with advanced breast cancer,results of a phase Ⅲ randomized double-blind trial[J].J Clin Oncol,2000,18(7):1399-1411.
